


5 We Claim:

1. A compound having the Formula I



wherein


- 10 R^1 is $-\text{CO}_2\text{CH}_3$ or $-\text{H}$;
 R^2 is $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{CO}_2\text{A}$, and $-\text{CH}_2\text{CH}_2\text{OA}$, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and
 R^3 is $-\text{H}$, $-\text{CO}_2\text{CH}_2\text{CH}_3$, $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$ and $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$; or a pharmaceutically acceptable salt of said
 15 compound with the proviso that
 if R^1 is $-\text{CO}_2\text{CH}_3$ and R^3 is $-\text{H}$, then R^2 is not $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{CO}_2\text{H}$;
 if R^1 is $-\text{CO}_2\text{CH}_3$ and R^3 is $-\text{CO}_2\text{CH}_2\text{CH}_3$, then R^2 is not $-\text{CH}_2\text{CH}_2$, $-\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{CO}_2\text{H}$; and
 20 if R^1 is $-\text{CO}_2\text{CH}_3$ and R^2 is $-\text{CH}_2\text{CH}_3$, then R^3 is not $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$.

2. The compound of claim 1 wherein R^1 is $-\text{CO}_2\text{CH}_3$, R^3 is $-\text{CO}_2\text{CH}_2\text{CH}_3$, and R^2 is selected from $-\text{CH}_2\text{CO}_2\text{A}$ or $-\text{CH}_2\text{CH}_2\text{OA}$.
 25
3. The compound of claim 1 wherein R^1 is $-\text{CO}_2\text{CH}_3$, R^3 is $-\text{H}$, and R^2 is selected from $-\text{CH}_2\text{CO}_2\text{A}$ or $-\text{CH}_2\text{CH}_2\text{OA}$.
4. The compound of claim 1 wherein R^1 and R^3 is H, and R^2 is selected
 30 from the group consisting of $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{CO}_2\text{A}$, and $-\text{CH}_2\text{CH}_2\text{OA}$.

5 5. The compound of claim 1 wherein R^1 is $-\text{CO}_2\text{CH}_3$, R^2 is $-\text{CH}_2\text{CH}_3$,
and R^3 is $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$.

6. A compound selected from the group consisting of
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-
10 trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-
trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-
carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl
15 ester;
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-
tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and
20 [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid.


7. A compound of Formula II



25 wherein R^5 is $-\text{CH}_2\text{CH}_3$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{A}$, $-\text{CH}_2\text{CH}_2\text{OH}$,
 $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{CH}_2\text{OA}$, $-\text{CH}_2\text{CH}_2\text{OSO}_3\text{H}$, $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$, -
 $\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CO}_2\text{H}$, and $-\text{C}(\text{O})\text{N}(\text{H})\text{C}(\text{O})\text{NH}_2$, and wherein A is 3,4,5-trihydroxy-
tetrahydropyran-2-carboxylic acid.

30 8. The compound of claim 7 wherein R^5 is selected from $-\text{CH}_2\text{CH}_3$ or
 $-\text{CO}_2\text{H}$.

- 5 9. A compound of Formula III



wherein R^6 is $-CH_2OA$, $-C(O)N(H)CH_2CO_2A$ and $-CH(SO_3H)N(H)CO_2CH_3$, and wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.

10

10. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 1 in the mammal.

15

11. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 6 or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal.

20

12. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of a compound of claim 7, 2-methyl-6-trifluoromethyl-quinoline, and (6-trifluoromethyl-quinolin-2-yl)methanol in the mammal.

25

30


13. A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-

5 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising
 monitoring the presence of a compound selected from the group consisting of
 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-
 trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-
 benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-
 10 trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-
 trifluoromethyl-benzoylamino)-acetic acid, and (3,5-Bis-trifluoromethyl-
 benzoylamino)- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid in the mammal.

14. A method for indicating the presence of or exposure to 4-[(3,5-bis-
 15 trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-
 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising
 monitoring the presence of a compound selected from the group consisting of
 3,5-bis-trifluoromethylbenzoic acid, 2-methyl-6-trifluoromethyl-quinoline, and
 6-trifluoromethyl-quinoline-2-carboxylic acid in the mammal.

20

15. A method for treating atherosclerosis comprising administering to a
 mammal an atherosclerosis treating amount of a compound of Formula I



wherein

25 R^1 is $-\text{CO}_2\text{CH}_3$ or $-\text{H}$;
 R^2 is $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{CO}_2\text{A}$, and -
 $\text{CH}_2\text{CH}_2\text{OA}$, wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and
 R^3 is $-\text{H}$, $-\text{CO}_2\text{CH}_2\text{CH}_3$, $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$,
 $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$ and $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$; a prodrug thereof, or a pharmaceutically
 30 acceptable salt of said compound or of said prodrug with the proviso that

- 5 if R¹ is -CO₂CH₃ and R³ is -H, then R² is not -CH₂CH₃, -CH₂CH₂OH, or -CH₂CO₂H;
- if R¹ is -CO₂CH₃ and R³ is -CO₂CH₂CH₃, then R² is not -CH₂CH₂, -CH₂CH₂OH, or -CH₂CO₂H; and
- if R¹ is -CO₂CH₃ and R² is -CH₂CH₃, then R³ is not -CO₂CH₂CH₂OH, or
- 10 -CO₂CH₂CO₂H, or a compound a compound selected from the group consisting of
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
- 15 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- 20 [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester;
- [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid, and
- a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or
- 25 of said prodrug.